Shilpa Medicare Ltd
NSE: SHILPAMED BSE: 530549
₹336.65
(-0.91%)
Wed, 11 Mar 2026, 05:29 am
Market Cap65.77B
PE Ratio43.90
Dividend0.15
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1987
- Shilpa Antibiotics Ltd was incorporated as a Private Limited Company in November 1987.
1989
- The commercial production of the Company had started in November 1989.
1992
- The Company had installed production facilities for manufacture of Sodium Methoxide.
- The Company secured Export orders from Stellar Exports Limited, Glaxo Limited and Deepak Nitrite Limited for Trimethoprim.
- The Company started manufacturing for both export and domestic markets.
1993
- The Company was converted into a Public Limited Company in November 1993.
2007
- Shilpa Medicare Ltd has entered into a memorandum of understanding with LOBA Finchemie AG, Austria, to acquire 100% shares of LOBA in an all-cash deal.
- The Company has splits its face value from Rs10/- to Rs2/-.
2008
- Shilpa Medicare Ltd has informed that the Board of Director of the Company has co-opted Mr Sunki Rajendra reddy S/o Mr Rajeshwara Reddy as an Additional Director.
- Shilpa Medicare Ltd has informed that the Board of Directors of the Company has co-opted Mr N P S Shinh S/o Mr S Prithipal Singh Shinh as an Additional Director.
2009
- Shilpa Medicare Ltd has informed that the Company has signed a MOU to form a joint venture company to manufacture drugs and pharmaceuticals with ICE S r l and PCA S p a of Italy.
2010
- Shilpa Medicare Limited has been granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride.
2011
- Shilpa Medicare Ltd acquired Controlling Stake in Nu Therapeutics.
2012
- Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
- The Board also recommended a dividend of 65% i e Re 1 30 (Rupee One & Thirty Paise Only) per equity share of Rs 2/- each.
- Shilpa Medicare Limited produced five key HIV medicines for sale in over 100 countries.
- Shilpa Medicare Ltd has announced the Company s State of art facility at Pharma Park Jadcherla (SEZ) has started functioning partially.
2013
- The Board also recommended a dividend of 65% i e Re 1 30 (Rupee One & Thirty Paise Only) per equity share of Rs 2/- each.
- Shilpa Medicare Limited produced five key HIV medicines for sale in over 100 countries.
- Shilpa Medicare Ltd has announced the Company s State of art facility at Pharma Park Jadcherla (SEZ) has started functioning partially.
2014
- The Company has recommended a dividend of Re 1/- (One) per equity share of Rs 2/- (Two) each (i e 50%).
2015
- India Pharma Awards 2015 Shilpa Medicare Ltd bagged UBM s Excellence in R&D Award.
- EUGMP received from Government of Upper Bavaria, Germany for Gemcitabine, Irinotecan HCl, Oxaliplatin and Temozolomide.
- Shilpa Medicare Ltd bagged Pharmexcil s Patent Award for securing the most number of product patents.
- Shilpa Medicare has benchmarked its quality processes against the world s best quality standards in various areas of operation.
- Shilpa Medicare has splits its face value from Rs 2 to Rs 1.
2016
- The Company be shifted from Plot No 10, Shop No 80, Rajendra Gunj, Raichur Karnataka- 584102 to #12-6-214/A1, Hyderabad Road, Raichur, Karnataka-584135 with effect from May 03, 2016.
- Shilpa Medicare to merge Navya Biologicals with itself.
2017
- The company has said that the scheme of merger of Navya Biologicals Private Limited with Shilpa Medicare Limited has been approved by the Hon ble National Company Law Tribunal.
2019
- Shilpa Medicare gets USFDA nod for cancer drug.
2020
- Shilpa Medicare Ltd launches first affordable generic drug to treat advanced kidney cancer.
- Shilpa Medicare launches anti-cancer drug - IBRUSHIL.
- Shilpa Medicare launched cancer drug at monthly therapy cost of Rs 6,440.
2021
- Shilpa Medicare ties up with Cadila Healthcare for production of ZyCoV-D vaccine.
- Shilpa Medicare arm inks pact with Dr Reddy s to manufacture Sputnik V vaccine.
- Shilpa Medicare gets tentative USFDA nod for Apremilast tablets.
- Shilpa Medicare Ltd has received Best District Export Excellence Award from FKCCI.
- Shilpa Medicare launches Sunitinib Capsules under brand name SINISHIL.
2022
- Shilpa Medicare Limited received NoC from RCGM, Dept. of Biotechnology for its Biosimilar Afliberce.
- The Prestigious PEL-HEMSI AWARD presented to Polymer Research & Technology Group of Shilpa Medicare Limited.
2023
- Shilpa Medicare Limited has launched ORAAL for the first time in India.
- Shilpa Medicare s New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by US FDA.
2024
- Shilpa Medicare receives marketing authorization from Germany for Amifampridine tablets.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800